ClinicalTrials.gg

Program

Sirolimus Topical Gel PTX-022

Its studies are mostly in Lymphangioma · Basal Cell Nevus Syndrome, led by Palvella Therapeutics.

Furthest: phase 3, since Apr 2, 20196 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Palvella Therapeutics62 open or runningphase 3since Apr 2, 2019Apr 2, 2019Aug 2027phase 2 · NCT07552077

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 2, 2019First study: phase 3 study in Pachyonychia CongenitaFirst studyNCT03920228 · 73 enrolled · United States
  2. Mar 6, 2020Phase 3 study in Pachyonychia CongenitaNCT04520750 · 36 enrolled · United States
  3. May 14, 2021Phase 2 study in Basal Cell Nevus SyndromeNCT04893486 · 73 enrolled · United States, United Kingdom
  4. Sep 8, 2021Phase 2 study in LymphangiomaNCT05050149 · 12 enrolled · United States
  5. Nov 8, 2022Phase 3 study in Pachyonychia CongenitaNCT05643872 · 45 planned · United States
  6. Apr 20, 2026Phase 2 study in AngiokeratomaNCT07552077 · 15 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 2 study in AngiokeratomaNCT07552077

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07552077Angiokeratoma · United States2RecruitingAug 202715
NCT05643872Pachyonychia Congenita · United States3RecruitingOct 202345
NCT05050149Lymphangioma · United States2CompletedNov 15, 202212
NCT04893486Basal Cell Nevus Syndrome · United States, United Kingdom2CompletedMar 13, 202373
NCT04520750Pachyonychia Congenita · United States3CompletedJun 30, 202136
NCT03920228Pachyonychia Congenita · United States3CompletedSep 19, 202073

How it is read

Names in the registry

  • “PTX-022”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.